FDA 483 - Louisville Reproductive Center - April 28, 2025

The FDA inspected Louisville Reproductive Center, a human tissue establishment, from April 23-28, 2025. The inspection revealed significant deficiencies in donor eligibility determination, specifically regarding the testing of semen donors for relevant communicable disease agents and the quarantine of HCT/Ps. These issues indicate a failure to ensure the safety and eligibility of donor tissues.